Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Net Income

Bottom-line profit after all expenses, interest, and taxes.

Champions Oncology, Inc.NASDAQ: CSBR

Net Income · Q3 FY2026 · quarter ended Jan 2026

Net income turns negative

Q3 FY2026 net income was -$279K, compared with $4.5M a year earlier. Trailing-twelve-month net income was -$2.28M. Over 3 fiscal years it compounded at +104.7% a year.

Context

  • Net income amounted to 8.3% of revenue in FY2025, down 6.3 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $1.66M (-64.7%) for the fiscal year ending Apr 2026, a slowdown from the +164.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJan 2026
-$279K-193.3% QoQ
Last fiscal yearApr 2025
$4.7M+164.6% YoY
LTMJan 2026
-$2.28M-135.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-106.2%+62.1%+168.3 pp
1 year+164.6%-64.7%-229.3 pp
3-year CAGR+104.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
4.7M USD
Year-over-year change
+164.6%
4-year CAGR
+89.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -135.5% is the 9th highest of 10, against a peer median of +29.4%.
  • Net income amounts to 3.9% of revenue for CSBR, versus a peer median of 4987.4%.
CSBR Competitors
Net Income for CSBR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$110M USD+489.6%——
CSBRChampions Oncology, Inc.LTM Jan 2026-$2.28M USD-135.5%+104.7%3.9%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$9.47M USD+39.5%—40.9%
IFRXInflaRx N.V.LTM Mar 2026-€42.91M EUR+4.0%—146303.9%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.1M USD+38.9%——
IMAImageneBio IncLTM Mar 2026-$45.07M USD-8.1%——
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
CNTBConnect Biopharma Holdings LimitedFY2025-$55.48M USD-255.0%—86687.5%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$87.07M USD-34.3%——
STROSutro Biopharma, Inc.LTM Mar 2026-$153.6M USD+37.4%—154.2%
Peer median (excluding CSBR) —+29.4%—4987.4%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.